Abstract

Background & Purpose: The SERAC1 gene mutation is rare disorder related to deficits in mitochondrial metabolism. Neuromotor development was not studied in literature for this type of patients based on physical therapy perspectives. However, in this case report, we described the Neuromotor development in a child with SERAC1 mutation at 18 months of age in order to plan for better rehabilitation care in pediatrics physical therapy profession. Case Description: A girl child with SERAC1 mutation (18 months old) presented to the physical therapy clinic with delay in Neuromotor development. During physical therapy evaluation, hearing and vision are intact, Able to distinguish her parents voice and able to recognize them. Speech is impaired, Head control and sitting was perceived at six months of age and became very dependent at 18 months of age. Grasping and reaching is not completely developed. Outcomes: The child was evaluated at the age of 12th and 18th month for normal development by using Alberta infant motor scale. The total score at 12 months was 17/58, and at 18th month was 13/58. We observed that the child development was less than 5th percentile of normal at both the measurements. We evaluated her neuromotor development by using Infant Neurological International Battery (INFANIB). The child was under abnormal category for neuromotor systems by having the total score 36/100. We used these two outcome measures as primary measure since they are the most common measures that used among pediatric physical therapists. Discussion: This indicates that the abnormality in motor development was due to the nature of the disease, which is consistent with clinical manifestations presented in the literature. Both the scales have good reliability and validity. INFANIB scale has good predictive validity, by seeing definite abnormality at the 18th month we can assume that child may not have normal development in future also. Conclusion: Future studies are required to explore the effectiveness of intensive rehabilitation therapy (including physical therapy, occupational therapy, and speech pathology services) in improving neuromotor development also to prevent any neuromotor regression for this type of disease. In addition, further investigations are required such as hearing test for better rehabilitation outcomes.

Keywords: Infanib · Pediatrics · Rehabilitation · Neuromotor Development

References

  1. 1.Wedatilake Y, Plagnol V, Anderson G, Paine SML, Clayton PT, Jacques TS, et al. Tubular aggregates caused by serine active site containing1(SERAC1) mutations in a patient with a mitochondrial encephalopathy. Neuropathol Appl Neurobiol 2015;41:399–402.
  2. 2.Wortmann SB, Vaz FM, Gardeitchik T, Vissers LELM, Renkema GH, SchuursHoeijmakers JHM, et al. Mutations in the phospholipid remodeling gene Neuro motor development in a girl with SERAC 1 gene dysfunction from Kingdom of Saudi Arabia. A case study 45 Majmaah Journal of Health Sciences ,Vol. 6, Issue 1, March 2018, Rajab - 1439 SERAC1 impair mitochondrial function and intracellular cholesterol trafficking and cause dystonia and deafness. Nat Genet 2012;44:797–802.
  3. 3.Lumish HS, Yang Y, Xia F, Wilson A, Chung WK. The Expanding MEGDEL Phenotype: Optic Nerve Atrophy, Microcephaly, and Myoclonic Epilepsy in a Child with SERAC1 Mutations. JIMD Rep 2014;16:75–9.
  4. 4.Dweikat IM, Abdelrazeq S, Ayesh S, Jundi T. MEGDEL Syndrome in a Child From Palestine: Report of a Novel Mutation in SERAC1 Gene. J Child Neurol 2015;30:1053–6.
  5. 5.Tort F, García-Silva MT, Ferrer-Cortès X, Navarro-Sastre A, Garcia-Villoria J, Coll MJ, et al. Exome sequencing identifies a new mutation in SERAC1 in a patient with 3-methylglutaconic aciduria. Mol Genet Metab 2013;110:73–7.
  6. 6.Wortmann S, Rodenburg RJT, Huizing M, Loupatty FJ, de Koning T, Kluijtmans LAJ, et al. Association of 3-methylglutaconic aciduria with sensori-neural deafness, encephalopathy, and Leigh-like syndrome (MEGDEL association) in four patients with a disorder of the oxidative phosphorylation. Mol Genet Metab 2006;88:47–52.
  7. 7.Sarig O, Goldsher D, Nousbeck J, FuchsTelem D, Cohen-Katsenelson K, Iancu TC, 46 et al. Infantile mitochondrial hepatopathy is a cardinal feature of MEGDEL syndrome (3-Methylglutaconic aciduria type IV with sensorineural deafness, encephalopathy and leigh-Like Syndrome) caused by novel mutations in SERAC1. Am J Med Genet Part A 2013;161:2204–15.
  8. 8.Piper MC, Pinnell LE, Darrah J, Maguire T, Byrne PJ. Construction and validatikon of the Alberta Infant Motor Scale (AIMS). Can. J. Public Heal., vol. 83, 1992.
  9. 9.Ellison PH, Horn JL, Browning C a. Construction of an Infant Neurological International Battery (Infanib) for the assessment of neurological integrity in infancy. Phys Ther 1985;65:1326–31.
  10. 10.Ellison PH. Scoring sheet for the Infant Neurological International Battery (INFANIB). Suggestion from the field. Phys Ther 1986;66:548–50.
  11. 11.Russell DJ, Rosenbaum PL, Avery LM, Lane M. GMFM Gross Motor Function Measure (GMFM-66 and GMFM-88) user’s manual. Cambridge: Cambridge University Press; 2002
  12. 12.Ünal Ö, Köksal Özgül R, Yücel D, Yalnızoğlu D, Tokatlı A, Serap Sivri H, et al. Two Turkish siblings with MEGDEL syndrome due to novel SERAC1 gene mutation. Turk J Pediatr 2015;57:388–93. Neuro motor development in a girl with SERAC 1 gene dysfunction from Kingdom of Saudi Arabia. A case study Majmaah Journal of Health Sciences ,Vol. 6, Issue 1, March 2018, Rajab - 1439
  13. 13.Charpak N, De La Hoz AM, Villegas J, Gil F. Discriminant ability of the Infant Neurological International Battery (INFANIB) as a screening tool for the neurological follow-up of highrisk infants in Colombia. Acta Paediatr Int J Paediatr 2016;105:e195–9.
  14. 14.Spittle AJ, Doyle LW, Boyd RN. A systematic review of the clinimetric properties of neuromotor assessments for preterm infants during the first year of life. Dev Med Child Neurol 2008;50:254–66
  15. 15.Luo F, Chen Z, Ma XL, Lin HJ, Bao Y, Wang CH, et al. Infant neurological international battery predicts neurological outcomes of preterm infants discharged from theneonatal intensive care unit. Chinese J Contemp Pediatr 2013;15:5–8 Validation of the Gross Motor Function Measure for use in children and adolescents with traumatic brain injuries. Pediatrics 2007;120:e880-6.
  16. 16.Mahasup N, Sritipsukho P, Lekskulchai R, Keawutan P. Inter-rater and intra-rater reliability of the gross motor function measure (GMFM-66) by Thai pediatric physical therapists. J Med Assoc Thai 2011;94 Suppl 7.
  17. 17.Alotaibi M, Long T, Kennedy E, Bavishi S. The efficacy of GMFM-88 and GMFM-66 to detect changes in gross motor function in children with cerebral palsy (CP): a literature review. Disabil Rehabil 2014;36:617–27.
  18. 18.Soleimani F, Dadkhah A. Validity and reliability of infant Neurological International Battery for detection of gross motor developmental delay in Iran. Child Care Health Dev 2007;33:262–5..
  19. 19.Russell DJ, Avery LM, Rosenbaum PL, Raina PS, Walter SD, Palisano RJ. Improved scaling of the gross motor function measure for children with cerebral palsy: evidence of reliability and validity. Phys Ther 2000;80:873–85.
  20. 20.Linder-Lucht M, Othmer V, Walther M, Vry J, Michaelis U, Stein S, et al. Neuro motor development in a girl with SERAC 1 gene dysfunction from Kingdom of Saudi Arabia. A case study 47
Majmaah Journal of Health Sciences · eISSN 1658-8223 · Majmaah University · open access